GlobeNewswire

Unprecedented worldwide support for the Global Partnership for Education and addressing the global learning crisis

Dela

DAKAR, Senegal, Feb. 03, 2018 (GLOBE NEWSWIRE) -- Ten current and three former heads of state and more than 60 ministers gathered at the Global Partnership for Education (GPE) Financing Conference, making this the highest-level education financing event of its kind.

The conference, co-hosted by President Macky Sall of the Republic of Senegal and President Emmanuel Macron of the French Republic, marks the first time an education financing conference has been hosted by a G7 leader and the president of a developing country.

More than 1200 participants attended including leaders from UNESCO, UNICEF, the World Bank, civil society, philanthropic foundations and the private sector. Rihanna, GPE's Global Ambassador supported by Global Citizen, also participated.

The size and nature of the attendance at the conference was a visible demonstration of the strengthened global political will to ensure every child is in school and learning. This heightened momentum will enable the Global Partnership for Education to reach the goal of providing US$2 billion a year by 2020 for education planning and delivery to support children's learning in developing countries.

Donor countries pledged US$2.3 billion in financing to GPE. This is a substantial increase in funding compared to the US$1.3 billion contributed over the past three years. In addition, several donor countries have indicated their intention to pledge further funds over the course of the financing period.

The biggest source of education financing comes from developing countries themselves. More than 50 developing countries announced they would increase public expenditures for education for the period of 2018 to 2020 to a total of US$110 billion, compared to US$80 billion between 2015 and 2017.

GPE encourages developing countries to increase their share of education spending to 20% of their overall budget. Of those governments committing today, over two-thirds will have reached that goal by 2020.

"I am energized by the generosity and determination we have seen here today to ensure every child and young person has access to a quality education. After today's commitments, we are seeing a clear trend to seriously address the global learning crisis," said Julia Gillard, Board Chair of the Global Partnership for Education and former Prime Minister of Australia. "The success of the conference marks a turning point for global political support for education financing and brings a new breadth and depth to our partnership."

At the conference, the United Arab Emirates joined GPE, becoming the first Arab donor and pledging US$100 million. Senegal, in addition to pledging to increase its own expenditure on education, became GPE's first African donor. The Netherlands and Spain renewed their involvement, and China attended for the first time.

"The unprecedented support today means that the Global Partnership for Education can continue to focus on the most excluded and vulnerable children and work to extend assistance to up to 89 countries, which are home to 870 million children and 78 percent of the world's out-of-school children," said Alice Albright, Chief Executive Officer, Global Partnership for Education.

The Global Partnership for Education's funding model is a catalyst for education investment, working hand in hand with governments of low-income and lower middle-income countries to strengthen their education systems. The Global Partnership for Education supports governments to develop robust national education plans so that funds can then be channeled into their priority areas with confidence that they will contribute to improved quality of education for all children. 

The conference was sponsored by: Ecobank, the Pan African Bank; Fondation Sonatel; and Altissia, and supported by Girls Not Brides; Global Campaign for Education; Global Citizen; Malala Fund; ONE; Plan International; RESULTS; and Women Deliver.

Video: https://www.youtube.com/gpforeducation

Conference Online Media Center:  https://www.globalpartnership.org/funding/replenishment/gpe-replenishment-media

Media contact

Alexandra Humme, ahumme@globalpartnership.org, tel: + 1 202 492 8890

For more information on the work of the Global Partnership for Education visit:

www.globalpartnership.org 
facebook.com/globalpartnership
twitter.com/gpforeducation

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ba917718-02da-4e22-8af8-d9e0c51153da




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Global Partnership for Education via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum